Similar Safety and Efficacy of Once- and Twice-Daily Lopinavir/Ritonavir Tablets in Treatment-Experienced HIV-1–Infected Subjects at 48 Weeks-Reference-Cited by-同舟云学术

Similar Safety and Efficacy of Once- and Twice-Daily Lopinavir/Ritonavir Tablets in Treatment-Experienced HIV-1–Infected Subjects at 48 Weeks

Published:2010-06-01 Issue:2 Volume:54 Page:143-151
ISSN:1525-4135
Container-title:JAIDS Journal of Acquired Immune Deficiency Syndromes
language:en
Short-container-title:

Author:

Zajdenverg Roberto,Podsadecki Thomas J,Badal-Faesen Sharlaa,Andrade-Villanueva Jaime,Gathe Joseph,Mingrone Horacio,Fredrick Linda M,Gaultier Isabelle A,Woodward W Chris,Bernstein Barry M

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Infectious Diseases

Reference20 articles.

1. Survival of persons with and without HIV infection in Denmark, 1995-2005.;Lohse;Ann Intern Med,2008

2. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection.;Paterson;Ann Intern Med,2000

3. Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy: self-report of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence.;Stone;J Acquir Immune Defic Syndr,2004

4. Randomization to once-daily stavudine extended release/lamivudine/efavirenz versus a more frequent regimen improves adherence while maintaining viral suppression.;Boyle;HIV Clin Trials,2008

5. Efficacy and safety of once-daily regimens in the treatment of HIV infection.;Molina;Drugs,2008

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Thirteen-year viral suppression and immunologic recovery of LPV/r-based regimens in pediatric HIV treatment: a multicenter cohort study in resource-constrained settings of China;Frontiers in Medicine;2023-12-22

2. The evolution of clinical study design in heavily treatment-experienced persons with HIV: A critical review;Antiviral Therapy;2023-05-22

3. Sustained Viral Suppression in HIV-infected Children on Once-daily Lopinavir/Ritonavir in Clinical Practice;Pediatric Infectious Disease Journal;2017-10

4. Cost-effectiveness of once-daily versus twice-daily regimens in the treatment of HIV infection in sub-Saharan Africa: a probabilistic decision model;F1000Research;2016-11-16

5. No Need for Lopinavir Dose Adjustment during Pregnancy: a Population Pharmacokinetic and Exposure-Response Analysis in Pregnant and Nonpregnant HIV-Infected Subjects;Antimicrobial Agents and Chemotherapy;2016-01